These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 7681806

  • 1. Clinical remission criteria for epithelial carcinoma of the ovary.
    Morikawa Y, Kawai M, Kano T, Kikkawa F, Oguchi H, Nakashima N, Ishizuka T, Furuhashi Y, Hattori SE, Kuzuya K.
    Gynecol Oncol; 1993 Mar; 48(3):342-8. PubMed ID: 7681806
    [Abstract] [Full Text] [Related]

  • 2. [The therapeutic value of second-look laparotomy in advanced ovarian carcinoma].
    Schneider J, Martin M, Erasun F, Matia JC, Rodriguez-Escudero FJ.
    Zentralbl Gynakol; 1988 Mar; 110(22):1443-8. PubMed ID: 3223119
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial of cisplatin, vinblastine, and bleomycin versus cyclophosphamide, aclacinomycin, and cisplatin in epithelial ovarian cancer.
    Tokuhashi Y, Kikkawa F, Tamakoshi K, Suganuma N, Kuzuya K, Arii Y, Kawai M, Hattori S, Kobayashi I, Furuhashi Y, Nakashima N, Tomoda Y.
    Oncology; 1997 Mar; 54(4):281-6. PubMed ID: 9216851
    [Abstract] [Full Text] [Related]

  • 4. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study.
    Bertelsen K.
    Gynecol Oncol; 1990 Aug; 38(2):203-9. PubMed ID: 2167280
    [Abstract] [Full Text] [Related]

  • 5. [Effect of chemotherapy on the prognosis of ovarian cancer].
    Sugawa T, Umesaki N, Yajima A, Satoh S, Terashima Y, Ochiai K, Tomoda Y, Kanoh T, Noda K, Yakushiji M.
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Sep; 44(9):1135-41. PubMed ID: 1333504
    [Abstract] [Full Text] [Related]

  • 6. Place of second-look laparotomy after 18 courses of chemotherapy in epithelial ovarian cancer.
    Ngan HY, Wong LC, Ma HK.
    Aust N Z J Obstet Gynaecol; 1989 Feb; 29(1):52-4. PubMed ID: 2562603
    [Abstract] [Full Text] [Related]

  • 7. Randomized trial of cisplatin and carboplatin versus cisplatin, vinblastine and bleomycin in ovarian cancer.
    Kikkawa F, Matsuzawa K, Arii Y, Kawai M, Kobayashi I, Nakashima N, Mizutani S.
    Gynecol Obstet Invest; 2000 Feb; 50(4):269-74. PubMed ID: 11093052
    [Abstract] [Full Text] [Related]

  • 8. Cisplatin based combination chemotherapy in the treatment of stage III ovarian epithelial tumors of low malignant potential.
    Yazigi R, Munoz AK, Sandstad J, Lifshitz S, Choi DJ.
    Eur J Gynaecol Oncol; 1991 Feb; 12(6):451-5. PubMed ID: 1809577
    [Abstract] [Full Text] [Related]

  • 9. Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients.
    Brower MS, Coleman M, Pasmantier MW, Silver RT, Mamaril AP, Quiguyan CC.
    Med Pediatr Oncol; 1984 Feb; 12(1):17-24. PubMed ID: 6321930
    [Abstract] [Full Text] [Related]

  • 10. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
    Del Campo JM, Felip E, Rubio D, Vidal R, Bermejo B, Colomer R, Zanon V.
    Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
    [Abstract] [Full Text] [Related]

  • 11. [The indications for second-look laparotomy in ovarian cancer patients].
    Gulo EI, Vinokurov VL, Bokhman IaV.
    Vopr Onkol; 1992 Apr; 38(5):616-23. PubMed ID: 1300762
    [Abstract] [Full Text] [Related]

  • 12. Second-look laparotomy after chemotherapy in the management of ovarian malignancy.
    Smirz LR, Stehman FB, Ulbright TM, Sutton GP, Ehrlich CE.
    Am J Obstet Gynecol; 1985 Jul 15; 152(6 Pt 1):661-8. PubMed ID: 4040706
    [Abstract] [Full Text] [Related]

  • 13. Whole abdominal and pelvic irradiation in patients with minimal disease at second-look surgical reassessment for ovarian carcinoma.
    Hoskins WJ, Lichter AS, Whittington R, Artman LE, Bibro MC, Park RC.
    Gynecol Oncol; 1985 Mar 15; 20(3):271-80. PubMed ID: 3972290
    [Abstract] [Full Text] [Related]

  • 14. Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. The influence of optimum pretreatment surgical resection.
    Barlow JJ, Lele SB, Emrich LJ.
    Am J Obstet Gynecol; 1985 Jun 01; 152(3):310-4. PubMed ID: 2988337
    [Abstract] [Full Text] [Related]

  • 15. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
    Lancet; 1987 Aug 15; 2(8555):353-9. PubMed ID: 2886821
    [Abstract] [Full Text] [Related]

  • 16. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.
    Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N.
    Obstet Gynecol; 2002 Aug 15; 100(2):281-7. PubMed ID: 12151151
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
    Skírnisdóttir I, Lindborg K, Sorbe B.
    Oncol Rep; 2007 Nov 15; 18(5):1249-56. PubMed ID: 17914581
    [Abstract] [Full Text] [Related]

  • 18. Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy.
    Sorbe B.
    Int J Gynecol Cancer; 2003 Nov 15; 13 Suppl 2():192-5. PubMed ID: 14656279
    [Abstract] [Full Text] [Related]

  • 19. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
    Zhao D, Wu LY, Wang XB, Li XG.
    Asian Pac J Cancer Prev; 2015 Nov 15; 16(6):2369-73. PubMed ID: 25824766
    [Abstract] [Full Text] [Related]

  • 20. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ, Bristow RE, Ryu HS.
    Ann Surg Oncol; 2012 Dec 15; 19(13):4059-67. PubMed ID: 22766983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.